Published in Biochemistry on December 07, 2006
Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation. Proc Natl Acad Sci U S A (2010) 1.37
Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. EMBO Rep (2010) 1.17
Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS One (2010) 1.13
Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol (2014) 0.99
Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease. PLoS One (2011) 0.94
The influence of vesicle size and composition on alpha-synuclein structure and stability. Biophys J (2009) 0.93
Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease. Cell Death Differ (2011) 0.90
Probing the micelle-bound aggregation-prone state of α-synuclein with (19)F NMR spectroscopy. Chembiochem (2010) 0.85
Α-synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson's disease. Brain Pathol (2011) 0.84
Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J Inorg Biochem (2009) 0.83
Lipid peroxidation is essential for α-synuclein-induced cell death. J Neurochem (2015) 0.83
New evidence on α-synuclein and Tau binding to conformation and sequence specific GC* rich DNA: Relevance to neurological disorders. J Pharm Bioallied Sci (2012) 0.81
Dietary factors in the etiology of Parkinson's disease. Biomed Res Int (2015) 0.81
Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies. Perspect Medicin Chem (2008) 0.80
Oligomerization of Cu,Zn-Superoxide Dismutase (SOD1) by Docosahexaenoic Acid and Its Hydroperoxides In Vitro: Aggregation Dependence on Fatty Acid Unsaturation and Thiols. PLoS One (2015) 0.75
Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein. Sci Rep (2016) 0.75
The influence of N-terminal acetylation on micelle-induced conformational changes and aggregation of α-Synuclein. PLoS One (2017) 0.75
α-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. J Biol Chem (2017) 0.75
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Tau pathology and neurodegeneration. Lancet Neurol (2013) 2.66
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Vesicular restriction of synaptobrevin suggests a role for calcium in membrane fusion. Nature (2002) 2.11
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem (2004) 2.11
Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem (2002) 2.07
Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J (2003) 2.07
The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett (2006) 2.04
Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis. Neuron (2009) 2.03
Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine (2010) 1.91
p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J (2005) 1.90
Proteasomal degradation of tau protein. J Neurochem (2002) 1.88
Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature (2006) 1.86
Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry (2006) 1.69
Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A (2003) 1.67
Arachidonic acid allows SNARE complex formation in the presence of Munc18. Chem Biol (2005) 1.65
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett (2004) 1.60
Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci (2006) 1.57
Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain (2012) 1.55
Botulinum protease-cleaved SNARE fragments induce cytotoxicity in neuroblastoma cells. J Neurochem (2014) 1.49
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain (2010) 1.38
Interaction of tau protein with the dynactin complex. EMBO J (2007) 1.33
A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol (2014) 1.32
Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol (2007) 1.32
PART is part of Alzheimer disease. Acta Neuropathol (2015) 1.31
VAMP4 directs synaptic vesicles to a pool that selectively maintains asynchronous neurotransmission. Nat Neurosci (2012) 1.30
Synaptotagmin interaction with the syntaxin/SNAP-25 dimer is mediated by an evolutionarily conserved motif and is sensitive to inositol hexakisphosphate. J Biol Chem (2004) 1.30
Mechanism of calcium-independent synaptotagmin binding to target SNAREs. J Biol Chem (2002) 1.27
Munc18-1 is critical for plasma membrane localization of syntaxin1 but not of SNAP-25 in PC12 cells. Mol Biol Cell (2007) 1.26
Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res (2010) 1.24
High affinity interaction of syntaxin and SNAP-25 on the plasma membrane is abolished by botulinum toxin E. J Biol Chem (2003) 1.23
A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, Abeta, and tau using the amino acid sequence alone. Protein Sci (2007) 1.22
White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol (2008) 1.21
Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.21
Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. J Neurochem (2006) 1.21
Conserved prefusion protein assembly in regulated exocytosis. Mol Biol Cell (2005) 1.20
Action of complexin on SNARE complex. J Biol Chem (2002) 1.19
The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain (2007) 1.18
Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. EMBO Rep (2010) 1.17
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett (2009) 1.17
Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). J Neurochem (2004) 1.17
U.K. parents' decision-making about measles-mumps-rubella (MMR) vaccine 10 years after the MMR-autism controversy: a qualitative analysis. Vaccine (2012) 1.17
Stress- and mitogen-induced phosphorylation of the synapse-associated protein SAP90/PSD-95 by activation of SAPK3/p38gamma and ERK1/ERK2. Biochem J (2004) 1.16
In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem (2008) 1.13
Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. FEBS Lett (2007) 1.12
Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol (2004) 1.11
Cysteine misincorporation in bacterially expressed human alpha-synuclein. FEBS Lett (2006) 1.10
Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein. J Mol Biol (2007) 1.09
Mechanism of arachidonic acid action on syntaxin-Munc18. EMBO Rep (2007) 1.09
Neurexin Ibeta and neuroligin are localized on opposite membranes in mature central synapses. J Neurochem (2007) 1.07
Cell-mediated neuroprotection in a mouse model of human tauopathy. J Neurosci (2010) 1.07
A role for FKBP52 in Tau protein function. Proc Natl Acad Sci U S A (2010) 1.07
Circadian clocks and neurodegenerative diseases: time to aggregate? Curr Opin Neurobiol (2013) 1.07
Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. J Cell Sci (2005) 1.06
The value of incomplete mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 1.06
Tau gene (MAPT) sequence variation among primates. Gene (2004) 1.06
"Prion-like" templated misfolding in tauopathies. Brain Pathol (2013) 1.06
Getting muscles moving again after botulinum toxin: novel therapeutic challenges. Trends Mol Med (2003) 1.05
Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology (2008) 1.04
A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins. Eur J Biochem (2002) 1.03
Omission bias and vaccine rejection by parents of healthy children: implications for the influenza A/H1N1 vaccination programme. Vaccine (2010) 1.02
DOC2B acts as a calcium switch and enhances vesicle fusion. J Neurosci (2008) 1.02
Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies. J Neurosci (2013) 1.02
A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO Rep (2004) 1.01
Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol Aging (2009) 1.01
Inhibition of alpha-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. FEBS Lett (2009) 1.00
Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. FEBS Lett (2008) 1.00
Promiscuous interaction of SNAP-25 with all plasma membrane syntaxins in a neuroendocrine cell. Biochem J (2005) 0.99
Cross-linking of phospholipid membranes is a conserved property of calcium-sensitive synaptotagmins. J Mol Biol (2008) 0.99
Synaptotagmin interaction with SNAP-25 governs vesicle docking, priming, and fusion triggering. J Neurosci (2013) 0.99
Comparative analysis of tandem C2 domains from the mammalian synaptotagmin family. Biochem J (2004) 0.99
Early behavioural markers of disease in P301S tau transgenic mice. Behav Brain Res (2009) 0.99
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One (2013) 0.98
Self-assembly of SNARE fusion proteins into star-shaped oligomers. Biochem J (2005) 0.98
SNARE tagging allows stepwise assembly of a multimodular medicinal toxin. Proc Natl Acad Sci U S A (2010) 0.98
Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol (2013) 0.97
Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One (2012) 0.97
Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: development and validation of an evidence-based measurement instrument. Vaccine (2010) 0.94
Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol (2005) 0.92
A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. Ann Neurol (2002) 0.92
Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis (2013) 0.91
Detection of apoptosis using the C2A domain of synaptotagmin I. Bioconjug Chem (2004) 0.89
Phospholipases and fatty acid signalling in exocytosis. J Physiol (2007) 0.89
Reduced axonal transport and increased excitotoxic retinal ganglion cell degeneration in mice transgenic for human mutant P301S tau. PLoS One (2012) 0.89
Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett (2002) 0.88
Stimulation of autophagy is neuroprotective in a mouse model of human tauopathy. Autophagy (2012) 0.87
Re-assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity. Toxins (Basel) (2011) 0.87